Literature DB >> 15882131

Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.

Erin R Lepper1, Kees Nooter, Jaap Verweij, Milin R Acharya, William D Figg, Alex Sparreboom.   

Abstract

ATP-binding cassette (ABC) genes play a role in the resistance of malignant cells to anticancer agents. The ABC gene products, including ABCB1 (P-glycoprotein) and ABCG2 (breast cancer-resistance protein [BCRP], mitoxantrone-resistance protein [MXR], or ABC transporter in placenta [ABCP]), are also known to influence oral absorption and disposition of a wide variety of drugs. As a result, the expression levels of these proteins in humans have important consequences for an individual's susceptibility to certain drug-induced side effects, interactions, and treatment efficacy. Naturally occurring variants in ABC transporter genes have been identified that might affect the function and expression of the protein. This review focuses on recent advances in the pharmacogenetics of the ABC transporters ABCB1 and ABCG2, and discusses potential implications of genetic variants for the chemotherapeutic treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882131     DOI: 10.1517/14622416.6.2.115

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  36 in total

1.  Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome.

Authors:  Motofumi Tanaka; Taro Okazaki; Hideo Suzuki; James L Abbruzzese; Donghui Li
Journal:  Cancer       Date:  2010-10-04       Impact factor: 6.860

Review 2.  Nanoparticles: a promising modality in the treatment of sarcomas.

Authors:  Michiro Susa; Lara Milane; Mansoor M Amiji; Francis J Hornicek; Zhenfeng Duan
Journal:  Pharm Res       Date:  2010-05-27       Impact factor: 4.200

Review 3.  Genetic variation in drug transporters in ethnic populations.

Authors:  C D Cropp; S W Yee; K M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2008-06-04       Impact factor: 6.875

4.  Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.

Authors:  John F Deeken; Robert W Robey; Suneet Shukla; Kenneth Steadman; Arup R Chakraborty; Balasubramanian Poonkuzhali; Erin G Schuetz; Susan Holbeck; Suresh V Ambudkar; Susan E Bates
Journal:  Mol Pharmacol       Date:  2009-07-24       Impact factor: 4.436

5.  Retrovirus-mediated multidrug resistance gene (MDR1) overexpression inhibits chemotherapy-induced toxicity of granulosa cells.

Authors:  Sana M Salih
Journal:  Fertil Steril       Date:  2011-02-12       Impact factor: 7.329

6.  Impact of incorporating ABCB1 and CYP4F2 polymorphisms in a pharmacogenetics-guided warfarin dosing algorithm for the Brazilian population.

Authors:  Letícia C Tavares; Nubia E Duarte; Leiliane R Marcatto; Renata A G Soares; Jose E Krieger; Alexandre C Pereira; Paulo Caleb Junior Lima Santos
Journal:  Eur J Clin Pharmacol       Date:  2018-07-26       Impact factor: 2.953

7.  Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.

Authors:  Xiaoyan Jiang; Donna Forrest; Franck Nicolini; Ali Turhan; Joelle Guilhot; Calvin Yip; Tessa Holyoake; Heather Jorgensen; Karen Lambie; Kyi Min Saw; Emily Pang; Ranko Vukovic; Paeta Lehn; Ashley Ringrose; Miao Yu; Ryan R Brinkman; Clay Smith; Allen Eaves; Connie Eaves
Journal:  Blood       Date:  2010-06-23       Impact factor: 22.113

Review 8.  Pharmacogenetics of membrane transporters: an update on current approaches.

Authors:  Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg
Journal:  Mol Biotechnol       Date:  2010-02       Impact factor: 2.695

9.  Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.

Authors:  Erin R Gardner; Nicola F Smith; William D Figg; Alex Sparreboom
Journal:  J Exp Clin Cancer Res       Date:  2009-07-10

10.  Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.

Authors:  Gabriele Buda; Deborah Ricci; C Chris Huang; Reyna Favis; Nadine Cohen; Sen H Zhuang; Jean-Luc Harousseau; Pieter Sonneveld; Joan Bladé; Robert Z Orlowski
Journal:  Ann Hematol       Date:  2010-06-08       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.